Janssen’s daratumumab accepted for accelerated CHMP assessment

Daratumumab is for treatment of European patients with heavily pre-treated multiple myeloma
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics mAbs Oncology Patient care anti-CD38 monoclonal antibody chmp daratumumab Latest News multiple myeloma Source Type: news